查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2111155

獸醫皮膚病市場預測至2034年－按產品類型、動物種類、疾病、給藥途徑、最終用戶、分銷管道和地區分類的全球分析

Veterinary Dermatology Market Forecasts to 2034 - Global Analysis By Product Type, Animal Type, Condition, Route of Administration, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球獸醫皮膚病市場規模將達到 25 億美元，並在預測期內以 9.7% 的複合年成長率成長，到 2034 年將達到 53 億美元。

獸醫皮膚病學是獸醫學的一個分支，專注於動物皮膚、毛髮、耳朵和指甲疾病的感染疾病，包括過敏性皮膚炎、寄生蟲性感染疾病、自體免疫皮膚感染、真菌性皮膚感染、自體免疫性皮膚病、皮膚癌和其他皮膚疾病。該市場涵蓋多種治療產品，例如透過外用、口服和靜脈注射途徑給藥的藥物、外用外用藥和注射劑。寵物數量的增加、動物皮膚病發病率的上升、人們對動物皮膚健康的日益關注以及獸醫皮膚病治療技術的進步，是推動各地區市場擴張的主要因素。

寵物數量的增加和皮膚病患病率的上升。

全球寵物數量的不斷成長以及伴侶動物皮膚病發病率的上升是推動獸醫皮膚病市場發展的主要因素。過敏性皮膚炎、寄生蟲感染疾病和細菌感染疾病等皮膚病是寵物就診最常見的原因之一。氣候變遷和過敏原增加等環境因素也加劇了皮膚病的發生率。寵物飼主越來越關注寵物的皮膚健康徵兆，並積極尋求治療。寵物「擬人化」以及人們日益成長的皮膚護理投入意願也促進了市場成長。隨著寵物數量的持續成長和皮膚病的持續流行，對獸醫皮膚病產品和服務的需求將繼續推動市場強勁擴張。

治療費用高昂，且飼主依從性低

獸醫皮膚病治療費用高昂以及飼主對治療方案的依從性差是限制市場發展的主要阻礙因素。慢性皮膚病通常需要長期治療，包括反覆就診、診斷測試和持續用藥，這給飼主飼主帶來了沉重的財務負擔。堅持執行複雜的治療方案，例如外用藥物、飲食管理和環境控制，並非易事。由於費用和複雜性而導致的治療中斷會影響治療效果和飼主的滿意度。這些依從性和費用的挑戰會限制治療效果和市場成長，尤其是在那些注重成本的寵物飼主身上。

開發先進和新型療法

獸醫皮膚病治療領域的持續創新為市場拓展帶來了巨大的機會。包括標靶治療和免疫調節劑在內的新型藥物正在改善慢性疾病（如過敏性皮膚炎和自體免疫疾病）的治療效果。具有更高滲透性和更長作用時間的先進外用製劑正在提高療效。包括單株抗體在內的生物製藥正逐漸成為獸醫皮膚病治療的新選擇。診斷檢測技術的進步，包括過敏檢測和分子診斷，正在推動標靶治療的發展。隨著治療選擇的增加和治療方案的改進，新產品正在不斷擴大市場佔有率，並擴大目標市場。

與替代療法和同類療法療法的競爭

來自同類療法、天然保健品和非處方藥等替代療法的激烈競爭對獸醫皮膚病市場構成重大威脅。尋求自然和整體療法的寵物飼主更傾向於選擇保健品和替代療法，而非傳統藥物。對替代產品的監管不足會影響消費者對其品質和療效的認知。非處方藥，例如藥用洗髮精和外用藥物，可能會降低處方藥的需求。競爭可能會限制藥品市場的成長，尤其是在飼主更傾向於選擇天然療法的慢性疾病領域。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對獸醫皮膚病市場產生了重大影響。初期，疫情封鎖期間，非緊急症狀的就診量下降。然而，疫情期間寵物領養數量激增，導致寵物數量增加，也催生了新的病患族群。遠距醫療在皮膚病領域的應用也隨之擴展，實現了遠距初步診斷和後續觀察。供應鏈中斷影響了藥品供應。疫情後，由於寵物飼養量的增加以及人們對寵物健康的持續關注，對皮膚病產品和服務的需求保持穩定。此次危機也加速了遠距醫療和數位健康解決方案在獸醫皮膚病領域的應用。

在預測期內，「過敏性皮膚炎」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，過敏性皮膚炎細分市場將佔據最大的市場佔有率，這主要得益於伴侶動物（尤其是犬類）過敏性皮膚病的高發病率以及先進治療方案的日益普及。過敏性皮膚炎，包括異位性皮膚炎和跳蚤過敏性皮膚炎，是獸醫臨床中最常見的皮膚病之一，需要持續治療。此細分市場受益於治療方案的擴展，包括新型免疫調節劑、標靶治療和先進的局部用藥製劑。飼主對過敏症狀和治療方案的認知不斷提高，也促進了診斷和治療率的提升。由於過敏性皮膚炎的發生率仍然很高，且治療方案不斷進步，預計在整個預測期內，該疾病細分市場將保持最大的市場佔有率。

在預測期內，注射劑藥物細分市場預計將呈現最高的複合年成長率。

在預測期內，注射療法領域預計將呈現最高的成長率，這主要得益於新型注射療法的研發，這些療法能夠提高療效、減少給藥頻率並增強飼主依從性。注射療法，包括單株抗體和長效皮質類固醇，與口服和外用藥物相比，能夠以更低的給藥頻率維持穩定的治療濃度。該領域受益於生物製藥在慢性疾病（包括異位性皮膚炎）治療中日益廣泛的應用。緩釋製劑和標靶給藥技術的進步正在拓展注射療法的選擇範圍。隨著新型注射療法獲得市場認可以及治療方案的不斷完善，注射療法有望成為給藥途徑細分市場中成長最快的領域。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這主要得益於其較高的寵物擁有率、在獸醫皮膚病學方面的巨額支出以及完善的醫療保健基礎設施。美國透過對皮膚病學相關產品和服務的大量投資，推動了區域市場的成長。人們對皮膚疾病及其治療方案的高度認知，提高了診斷和治療率。強大的製藥公司和獸醫專科診所的存在，推動了創新。寵物保險的廣泛普及有助於減輕治療費用負擔。高額的寵物相關支出和先進的獸醫基礎設施，確保了北美在市場上的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於寵物擁有率的上升、可支配收入的增加以及中國、印度、澳大利亞和東南亞等國家獸醫皮膚病學意識的提高。該地區寵物數量的快速成長和中產階級的壯大，正在創造對皮膚病學相關產品和服務的顯著需求。獸醫實踐的現代化和藥物取得途徑的改善也有助於降低治療成本。先進療法的日益普及和寵物保險參保率的提高也有助於減輕治療的經濟負擔。隨著寵物醫療保健的進步和人們對皮膚病認知的提高，亞太地區正經歷著全球成長最快的獸醫皮膚病學市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球獸醫皮膚病市場：依產品類型分類

  • 抗生素
  • 抗真菌藥物
  • 驅蟲
  • 皮質類固醇
  • 單株抗體
  • 免疫調節劑
  • 藥用洗髮精和外用護理產品
  • 其他產品

第6章：全球獸醫皮膚病市場：依動物類型分類

  • 伴侶動物
    • 狗
    • 貓
    • 馬
    • 其他伴侶動物
  • 家畜
    • 牛
    • 豬
    • 綿羊和山羊
    • 家禽
    • 其他牲畜

第7章：全球獸醫皮膚病市場：依疾病分類

  • 過敏性皮膚炎
  • 寄生蟲性皮膚病
  • 細菌性皮膚感染疾病
  • 黴菌性皮膚感染疾病
  • 自體免疫皮膚病
  • 皮膚癌
  • 其他皮膚病

第8章：全球獸醫皮膚病市場：依給藥途徑分類

  • 外用
  • 口服
  • 注射藥物

第9章：全球獸醫皮膚病市場：依最終用戶分類

  • 動物醫院
  • 動物診所
  • 學術研究機構
  • 動物收容所和救援組織

第10章：全球獸醫皮膚病市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥局和電子商務
  • 獸藥批發商

第11章：全球獸醫皮膚病市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品上市及法規核准
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim Animal Health
  • Merck Animal Health
  • Virbac SA
  • Dechra Pharmaceuticals PLC
  • Ceva Sante Animale
  • Vetoquinol SA
  • Norbrook Laboratories Ltd.
  • Bimeda Holdings PLC
  • Phibro Animal Health Corporation
  • Chanelle Pharma
  • Dermcare Vet Pty Ltd.
  • Animal Dermatology Group, Inc.
  • IDEXX Laboratories, Inc.
  • Antech Diagnostics, Inc.
Product Code: SMRC38894

According to Stratistics MRC, the Global Veterinary Dermatology Market is accounted for $2.5 billion in 2026 and is expected to reach $5.3 billion by 2034 growing at a CAGR of 9.7% during the forecast period. Veterinary dermatology is a specialized branch of veterinary medicine focused on the diagnosis, treatment, and management of skin, hair, ear, and nail conditions in animals, including allergic dermatitis, parasitic skin diseases, bacterial skin infections, fungal skin infections, autoimmune skin diseases, skin cancer, and other dermatological conditions. The market encompasses therapeutic products including pharmaceuticals, topical treatments, and injectable therapies administered through topical, oral, and injectable routes. Growing pet ownership, increasing prevalence of skin conditions in animals, rising awareness of animal dermatological health, and technological advancements in veterinary dermatology treatments are key drivers of market expansion across all regions.

Market Dynamics:

Driver:

Increasing pet ownership and rising prevalence of dermatological conditions

The growing global pet population and increasing prevalence of skin conditions in companion animals are primary drivers for the veterinary dermatology market. Skin conditions including allergic dermatitis, parasitic infections, and bacterial infections are among the most common reasons for veterinary visits. Environmental factors including climate change and increasing allergens are contributing to rising dermatological condition rates. Pet owners are increasingly aware of skin health signs and seeking treatment for their animals. The humanization of pets and willingness to invest in dermatological care support market growth. As pet ownership continues rising and skin conditions remain prevalent, demand for veterinary dermatology products and services sustains strong market expansion.

Restraint:

High treatment costs and limited owner compliance

The significant costs associated with veterinary dermatology treatments and limited owner compliance with treatment regimens represent a major restraint for the market. Chronic dermatological conditions often require long-term treatment, including repeated consultations, diagnostic testing, and ongoing medication, creating substantial financial burden. Owner compliance with complex treatment protocols including topical applications, dietary management, and environmental controls can be challenging. Treatment abandonment due to cost or complexity affects outcomes and patient satisfaction. These compliance and cost challenges may limit treatment effectiveness and market growth, particularly among cost-conscious pet owners.

Opportunity:

Development of advanced therapeutics and novel treatment modalities

Continuous innovation in veterinary dermatology therapeutics presents significant opportunities for market expansion. Novel pharmaceuticals including targeted therapies and immunomodulators are improving treatment outcomes for chronic conditions including allergic dermatitis and autoimmune diseases. Advanced topical formulations with improved penetration and prolonged action are enhancing efficacy. Biologic therapies including monoclonal antibodies are emerging for veterinary dermatological conditions. Advances in diagnostic testing including allergy testing and molecular diagnostics enable targeted treatment approaches. As therapeutic options expand and treatment protocols improve, new products capture growing market share, expanding the addressable market.

Threat:

Competition from alternative and homeopathic treatments

Intense competition from alternative therapies including homeopathic remedies, natural supplements, and over-the-counter products poses significant threats to the veterinary dermatology market. Pet owners seeking natural or holistic approaches may choose supplements and alternative treatments over conventional pharmaceuticals. Limited regulation of alternative products may affect quality and efficacy perceptions. Over-the-counter products including medicated shampoos and topical treatments may reduce prescription product demand. This competition may limit growth in pharmaceutical segments, particularly for chronic conditions where owner preferences for natural approaches are strong.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the veterinary dermatology market. Initial disruptions included reduced veterinary visits for non-urgent conditions during lockdowns. However, pet adoption surged during the pandemic, expanding the pet population and creating new patients. Telemedicine consultations for dermatological conditions expanded, enabling remote triage and follow-up. Supply chain disruptions affected pharmaceutical availability. Post-pandemic, elevated pet ownership and continued focus on pet health have sustained demand for dermatology products and services. The crisis accelerated adoption of remote consultation and digital health solutions in veterinary dermatology.

The Allergic Dermatitis segment is expected to be the largest during the forecast period

The Allergic Dermatitis segment is expected to account for the largest market share during the forecast period, driven by the high prevalence of allergic skin conditions in companion animals, particularly dogs, and the growing availability of advanced therapeutic options. Allergic dermatitis including atopic dermatitis and flea allergy dermatitis is among the most common dermatological conditions in veterinary practice, requiring ongoing management. The segment benefits from expanding therapeutic options including novel immunomodulators, targeted therapies, and advanced topical formulations. Growing owner awareness of allergy signs and treatment options supports diagnosis and treatment rates. As prevalence remains high and treatment protocols advance, allergic dermatitis maintains the largest condition segment share throughout the forecast period.

The Injectable segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Injectable segment is predicted to witness the highest growth rate, fueled by the development of novel injectable therapies offering improved efficacy, reduced dosing frequency, and enhanced owner compliance. Injectable treatments including monoclonal antibodies and long-acting corticosteroids provide consistent therapeutic levels with less frequent administration compared to oral or topical options. The segment benefits from growing adoption of biologic therapies for chronic conditions including atopic dermatitis. Advances in sustained-release formulations and targeted delivery are expanding injectable options. As novel injectable therapies gain market acceptance and treatment protocols evolve, the injectable route delivers the fastest administration segment growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, strong spending on veterinary dermatology care, and established veterinary healthcare infrastructure. The United States leads regional market growth with substantial investment in dermatology products and services. High awareness of skin conditions and treatment options supports diagnosis and treatment rates. Strong presence of pharmaceutical manufacturers and veterinary specialty practices drives innovation. Established pet insurance adoption supports affordability. With high pet spending and advanced veterinary infrastructure, North America maintains its dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rising pet ownership, increasing disposable incomes, and growing awareness of veterinary dermatology across countries including China, India, Australia, and Southeast Asia. The region's rapidly growing pet population and expanding middle class create substantial demand for dermatology products and services. Veterinary practice modernization and pharmaceutical access are improving. Growing availability of advanced treatments and increasing pet insurance adoption support affordability. As pet healthcare develops and awareness of dermatological conditions increases, Asia Pacific delivers the fastest veterinary dermatology market growth globally.

Key players in the market

Some of the key players in Veterinary Dermatology Market include Zoetis Inc., Elanco Animal Health Incorporated, Boehringer Ingelheim Animal Health, Merck Animal Health, Virbac S.A., Dechra Pharmaceuticals PLC, Ceva Sante Animale, Vetoquinol S.A., Norbrook Laboratories Ltd., Bimeda Holdings PLC, Phibro Animal Health Corporation, Chanelle Pharma, Dermcare Vet Pty Ltd., Animal Dermatology Group, Inc., IDEXX Laboratories, Inc., and Antech Diagnostics, Inc.

Key Developments:

In July 2026, Vetoquinol USA announced the release of NexHA(TM) (hyaluronate sodium) Injectable Solution in a new 3-vial box configuration, expanding its portfolio of targeted wound healing and connective tissue solutions.

In June 2026, Dechra officially opened its new global headquarters in Boston, Massachusetts, strengthening its U.S. operational presence and committing $60,000 in local life sciences community partnerships.

In March 2026, Zoetis entered into a definitive agreement to acquire Neogen Corporation's animal genomics business to expand its predictive health insights across companion animal care and livestock.

In February 2026, Elanco Animal Health reported receiving USDA approval for Befrena(TM), a new anti-IL31 monoclonal antibody injection targeting canine allergic and atopic dermatitis, as part of its fourth-quarter and full-year 2025 financial results.

Product Types Covered:

  • Antibacterial Drugs
  • Antifungal Drugs
  • Antiparasitic Drugs
  • Corticosteroids
  • Monoclonal Antibodies
  • Immunomodulators
  • Medicated Shampoos and Topical Care Products
  • Other Products

Animal Types Covered:

  • Companion Animals
  • Livestock Animals

Conditions Covered:

  • Allergic Dermatitis
  • Parasitic Skin Diseases
  • Bacterial Skin Infections
  • Fungal Skin Infections
  • Autoimmune Skin Diseases
  • Skin Cancer
  • Other Dermatological Conditions

Routes of Administration Covered:

  • Topical
  • Oral
  • Injectable

End Users Covered:

  • Veterinary Hospitals
  • Veterinary Clinics
  • Academic and Research Institutes
  • Animal Shelters and Rescue Organizations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies and E-Commerce
  • Veterinary Distributors

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Veterinary Dermatology Market, By Product Type

  • 5.1 Antibacterial Drugs
  • 5.2 Antifungal Drugs
  • 5.3 Antiparasitic Drugs
  • 5.4 Corticosteroids
  • 5.5 Monoclonal Antibodies
  • 5.6 Immunomodulators
  • 5.7 Medicated Shampoos and Topical Care Products
  • 5.8 Other Products

6 Global Veterinary Dermatology Market, By Animal Type

  • 6.1 Companion Animals
    • 6.1.1 Dogs
    • 6.1.2 Cats
    • 6.1.3 Horses
    • 6.1.4 Other Companion Animals
  • 6.2 Livestock Animals
    • 6.2.1 Cattle
    • 6.2.2 Swine
    • 6.2.3 Sheep and Goats
    • 6.2.4 Poultry
    • 6.2.5 Other Livestock Animals

7 Global Veterinary Dermatology Market, By Condition

  • 7.1 Allergic Dermatitis
  • 7.2 Parasitic Skin Diseases
  • 7.3 Bacterial Skin Infections
  • 7.4 Fungal Skin Infections
  • 7.5 Autoimmune Skin Diseases
  • 7.6 Skin Cancer
  • 7.7 Other Dermatological Conditions

8 Global Veterinary Dermatology Market, By Route of Administration

  • 8.1 Topical
  • 8.2 Oral
  • 8.3 Injectable

9 Global Veterinary Dermatology Market, By End User

  • 9.1 Veterinary Hospitals
  • 9.2 Veterinary Clinics
  • 9.3 Academic and Research Institutes
  • 9.4 Animal Shelters and Rescue Organizations

10 Global Veterinary Dermatology Market, By Distribution Channel

  • 10.1 Hospital Pharmacies
  • 10.2 Retail Pharmacies
  • 10.3 Online Pharmacies and E-Commerce
  • 10.4 Veterinary Distributors

11 Global Veterinary Dermatology Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Regulatory Approvals
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Zoetis Inc.
  • 14.2 Elanco Animal Health Incorporated
  • 14.3 Boehringer Ingelheim Animal Health
  • 14.4 Merck Animal Health
  • 14.5 Virbac S.A.
  • 14.6 Dechra Pharmaceuticals PLC
  • 14.7 Ceva Sante Animale
  • 14.8 Vetoquinol S.A.
  • 14.9 Norbrook Laboratories Ltd.
  • 14.10 Bimeda Holdings PLC
  • 14.11 Phibro Animal Health Corporation
  • 14.12 Chanelle Pharma
  • 14.13 Dermcare Vet Pty Ltd.
  • 14.14 Animal Dermatology Group, Inc.
  • 14.15 IDEXX Laboratories, Inc.
  • 14.16 Antech Diagnostics, Inc.

List of Tables

  • Table 1 Global Veterinary Dermatology Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Veterinary Dermatology Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Veterinary Dermatology Market Outlook, By Antibacterial Drugs (2023-2034) ($MN)
  • Table 4 Global Veterinary Dermatology Market Outlook, By Antifungal Drugs (2023-2034) ($MN)
  • Table 5 Global Veterinary Dermatology Market Outlook, By Antiparasitic Drugs (2023-2034) ($MN)
  • Table 6 Global Veterinary Dermatology Market Outlook, By Corticosteroids (2023-2034) ($MN)
  • Table 7 Global Veterinary Dermatology Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 8 Global Veterinary Dermatology Market Outlook, By Immunomodulators (2023-2034) ($MN)
  • Table 9 Global Veterinary Dermatology Market Outlook, By Medicated Shampoos and Topical Care Products (2023-2034) ($MN)
  • Table 10 Global Veterinary Dermatology Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 11 Global Veterinary Dermatology Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 12 Global Veterinary Dermatology Market Outlook, By Companion Animals (2023-2034) ($MN)
  • Table 13 Global Veterinary Dermatology Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 14 Global Veterinary Dermatology Market Outlook, By Cats (2023-2034) ($MN)
  • Table 15 Global Veterinary Dermatology Market Outlook, By Horses (2023-2034) ($MN)
  • Table 16 Global Veterinary Dermatology Market Outlook, By Other Companion Animals (2023-2034) ($MN)
  • Table 17 Global Veterinary Dermatology Market Outlook, By Livestock Animals (2023-2034) ($MN)
  • Table 18 Global Veterinary Dermatology Market Outlook, By Cattle (2023-2034) ($MN)
  • Table 19 Global Veterinary Dermatology Market Outlook, By Swine (2023-2034) ($MN)
  • Table 20 Global Veterinary Dermatology Market Outlook, By Sheep and Goats (2023-2034) ($MN)
  • Table 21 Global Veterinary Dermatology Market Outlook, By Poultry (2023-2034) ($MN)
  • Table 22 Global Veterinary Dermatology Market Outlook, By Other Livestock Animals (2023-2034) ($MN)
  • Table 23 Global Veterinary Dermatology Market Outlook, By Condition (2023-2034) ($MN)
  • Table 24 Global Veterinary Dermatology Market Outlook, By Allergic Dermatitis (2023-2034) ($MN)
  • Table 25 Global Veterinary Dermatology Market Outlook, By Parasitic Skin Diseases (2023-2034) ($MN)
  • Table 26 Global Veterinary Dermatology Market Outlook, By Bacterial Skin Infections (2023-2034) ($MN)
  • Table 27 Global Veterinary Dermatology Market Outlook, By Fungal Skin Infections (2023-2034) ($MN)
  • Table 28 Global Veterinary Dermatology Market Outlook, By Autoimmune Skin Diseases (2023-2034) ($MN)
  • Table 29 Global Veterinary Dermatology Market Outlook, By Skin Cancer (2023-2034) ($MN)
  • Table 30 Global Veterinary Dermatology Market Outlook, By Other Dermatological Conditions (2023-2034) ($MN)
  • Table 31 Global Veterinary Dermatology Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 32 Global Veterinary Dermatology Market Outlook, By Topical (2023-2034) ($MN)
  • Table 33 Global Veterinary Dermatology Market Outlook, By Oral (2023-2034) ($MN)
  • Table 34 Global Veterinary Dermatology Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 35 Global Veterinary Dermatology Market Outlook, By End User (2023-2034) ($MN)
  • Table 36 Global Veterinary Dermatology Market Outlook, By Veterinary Hospitals (2023-2034) ($MN)
  • Table 37 Global Veterinary Dermatology Market Outlook, By Veterinary Clinics (2023-2034) ($MN)
  • Table 38 Global Veterinary Dermatology Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 39 Global Veterinary Dermatology Market Outlook, By Animal Shelters and Rescue Organizations (2023-2034) ($MN)
  • Table 40 Global Veterinary Dermatology Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 41 Global Veterinary Dermatology Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 42 Global Veterinary Dermatology Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 43 Global Veterinary Dermatology Market Outlook, By Online Pharmacies and E-Commerce (2023-2034) ($MN)
  • Table 44 Global Veterinary Dermatology Market Outlook, By Veterinary Distributors (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.